Almirall is a global biopharmaceutical company dedicated primarily to medical dermatology and skin health. Headquartered in Barcelona, Spain, and founded in 1944, the company focuses on applying science to provide medical solutions for patients suffering from various skin diseases.

Core Focus:
The company’s main therapeutic area is medical dermatology, including treatments for conditions such as psoriasis, atopic dermatitis, acne, and actinic keratosis.

Global Presence:
Almirall’s products are available in over 100 countries across five continents, supported by 15 global affiliates.

Operations:
The company is engaged in the research, development, manufacture, and commercialization of both its own R&D and licensed drugs. It operates R&D centers and manufacturing plants in Europe.

Public Company:
Almirall is a publicly traded company, listed on the Spanish Stock Exchange (ticker: ALM).

Purpose:
Its stated purpose is to “Transform the patients’ world by helping them realize their hopes and dreams for a healthy life”.